25821 INDUSTRIAL BLVD., SUITE 100, HAYWARD, CA
Valion Bio, Inc. Enters $8.4M Securities Purchase Agreement with 3i
New Board Chair Brings Biotech Turnaround Experience to the Advancement of Entolimod
Successfully Formulate Oral Mucosal Entolimod; Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Announces Changes to Management and Board of Directors
Announces Reverse Stock Split
Amended material disclosure
Entry into Material Definitive Agreement with 3i for Series B Preferred Stock
Q2
Q1
FY 2025
Q3
FY 2024
RW
Effectiveness Notice
S-1
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Withdrawal of Offering Statement
Submission Upload
Correspondence
Deregistration Letter